- Pregnant women are excluded from this study because MPDL3280A, and other members of the immune checkpoint blocking class of agents, have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MPDL3280A, breastfeeding should be discontinued if the mother is treated with MPDL3280A.